GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051348111 | Esophagus | ESCC | negative regulation of transferase activity | 177/8552 | 268/18723 | 1.08e-11 | 4.00e-10 | 177 |
GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
GO:0001933111 | Esophagus | ESCC | negative regulation of protein phosphorylation | 213/8552 | 342/18723 | 3.54e-10 | 9.76e-09 | 213 |
GO:003367319 | Esophagus | ESCC | negative regulation of kinase activity | 154/8552 | 237/18723 | 1.38e-09 | 3.27e-08 | 154 |
GO:000646920 | Esophagus | ESCC | negative regulation of protein kinase activity | 140/8552 | 212/18723 | 1.53e-09 | 3.56e-08 | 140 |
GO:0001890110 | Esophagus | ESCC | placenta development | 98/8552 | 144/18723 | 4.46e-08 | 8.11e-07 | 98 |
GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:000189219 | Esophagus | ESCC | embryonic placenta development | 57/8552 | 82/18723 | 1.06e-05 | 1.01e-04 | 57 |
GO:00507322 | Esophagus | ESCC | negative regulation of peptidyl-tyrosine phosphorylation | 42/8552 | 59/18723 | 6.35e-05 | 4.84e-04 | 42 |
GO:00610997 | Esophagus | ESCC | negative regulation of protein tyrosine kinase activity | 25/8552 | 31/18723 | 7.13e-05 | 5.38e-04 | 25 |
GO:00485687 | Esophagus | ESCC | embryonic organ development | 228/8552 | 427/18723 | 7.28e-04 | 3.79e-03 | 228 |
GO:00182124 | Esophagus | ESCC | peptidyl-tyrosine modification | 202/8552 | 378/18723 | 1.34e-03 | 6.39e-03 | 202 |
GO:00181084 | Esophagus | ESCC | peptidyl-tyrosine phosphorylation | 200/8552 | 375/18723 | 1.60e-03 | 7.45e-03 | 200 |
GO:00607119 | Esophagus | ESCC | labyrinthine layer development | 30/8552 | 44/18723 | 2.14e-03 | 9.54e-03 | 30 |
GO:00507303 | Esophagus | ESCC | regulation of peptidyl-tyrosine phosphorylation | 144/8552 | 264/18723 | 2.22e-03 | 9.78e-03 | 144 |
GO:00610972 | Esophagus | ESCC | regulation of protein tyrosine kinase activity | 55/8552 | 90/18723 | 2.27e-03 | 9.99e-03 | 55 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GGN | SNV | Missense_Mutation | novel | c.1270N>T | p.Gly424Cys | p.G424C | Q86UU5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.835) | TCGA-AC-A62X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | novel | c.13C>A | p.Gln5Lys | p.Q5K | Q86UU5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.953) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
GGN | SNV | Missense_Mutation | novel | c.1646N>A | p.Arg549His | p.R549H | Q86UU5 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.88) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GGN | SNV | Missense_Mutation | | c.1893N>G | p.Ile631Met | p.I631M | Q86UU5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.975) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | novel | c.1667N>A | p.Val556Glu | p.V556E | Q86UU5 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.702) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
GGN | insertion | In_Frame_Ins | novel | c.1104_1105insAGC | p.Gly368_Ala369insSer | p.G368_A369insS | Q86UU5 | protein_coding | | | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
GGN | SNV | Missense_Mutation | | c.698N>T | p.Ala233Val | p.A233V | Q86UU5 | protein_coding | tolerated_low_confidence(0.38) | benign(0.005) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | | c.1648G>A | p.Glu550Lys | p.E550K | Q86UU5 | protein_coding | tolerated_low_confidence(0.11) | benign(0.091) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | | c.52N>A | p.Gln18Lys | p.Q18K | Q86UU5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.533) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | | c.1813N>T | p.Arg605Cys | p.R605C | Q86UU5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.992) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |